In Reply Dr Carminati provides an insightful commentary about our randomized clinical trial comparing bioresorbable and metallic occluders for transcatheter atrial septal defect closure. Unlike coronary stents typically used in older patient populations, metallic occluders are often implanted during childhood or early adulthood.
Their lifelong presence may have anatomical, psychological, and social implications—potentially limiting future transseptal access for procedures (such as atrial fibrillation ablation) and possibly affecting quality of life and psychosocial adaptation of individuals with congenital heart disease. In contrast, bioresorbable occluders leave no residual material after complete degradation.
JAMA (Journal of the American Medical Association) published a clinical update in Research Highlights on 24 Mar 2026.
The item focuses on Bioresorbable vs Metallic Occluder for Transcatheter Atrial Septal Defect Closure—Reply.
Review the original article for the full source wording and details.